VLA 0.00% $1.75 viralytics limited

Ann: New Data at SITC Meeting. Further Studies Announced, page-48

  1. 679 Posts.
    lightbulb Created with Sketch. 7
    I fail at to see how VLA cannot be on the radar of a big pharmaceutical company. CAVATAK has proven to substantially enhance results. We have the best results in the field, and the safety profile is also first class

    At some stage one of these big boys will put an offer on the table. Even if it’s just to keep the product from a competitor?

    We are releasing our results on the biggest stage in the world for pharmaceutical companies. They will be taking notice I believe. They have to. It’s just a matter of time
    Last edited by BaDMoNkEy: 15/11/17
 
watchlist Created with Sketch. Add VLA (ASX) to my watchlist

Currently unlisted public company.

arrow-down-2 Created with Sketch. arrow-down-2 Created with Sketch.